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a  b  s  t  r  a  c  t
Despite  the various  reports  on the  toxicity  of clove  oil  and  its major  component  eugenol,  systematic
evaluations  on  the  safety  of polyphenolic  extracts  of  clove  buds  have not  been  reported.  Considering  the
health  beneﬁcial  pharmacological  effects  and  recent  use  of  clove  polyphenols  as dietary  supplements,
the  present  study  investigated  the safety  of  a standardized  polyphenolic  extract  of  clove  buds (Clovi-
nol),  as  assessed  by oral  acute  (5  g/kg  b.wt.  for 14  days)  and  subchronic  (0.25,  0.5  and 1 g/kg  b.wt. for  90
days)  toxicity  studies  on  Wistar  rats  and  mutagenicity  studies  employing  Salmonella  typhimurium  strains.
Administration  of  Clovinol  did  not  result  in  any  toxicologically  signiﬁcant  changes  in clinical/behavioural
observations,  ophthalmic  examinations,  body  weights,  organ  weights,  feed  consumption,  urinalysis,
hematology  and  clinical  biochemistry  parameters  when  compared  to  the  untreated  control  group  ofubchronic toxicity
utagenicity
enotoxicity
animals,  indicating  the  no observed-adverse-effect  level  (NOAEL)  as  1000  mg/kg  b.wt./day;  the  highest
dose  tested.  Terminal  necropsy  did  not  reveal  any  treatment-related  histopathology  changes.  Clovinol  did
not show  genotoxicity  when  tested  on TA-98,  TA-100  and  TA-102  with  or without  metabolic  activation;
rather  exhibited  signiﬁcant  antimutagenic  potential  against  the  known  mutagens,  sodium  azide,  NPD  and
tobacco  as  well  as against  2-acetamidoﬂourene,  which  needed  metabolic  activation  for  mutagenicity.
© 2016  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
The development and application of natural medicines and
ealth promoting/guarding botanical agents is of great inter-
st since thousands of years. Spices, a group of aromatic plants
idely in use as food ﬂavors and preservatives, constitute an
mportant class of medicinal plants well-practiced in Indian and
hinese traditional systems of medicine. Modern scientiﬁc research
as unraveled the medicinal secrets of spices and delineated
heir phytochemicals (phytonutrients) responsible for the health
eneﬁcial pharmacological activities [21,13,32]. The dried ﬂower
uds of clove (Syzygium aromaticum L.), an evergreen tropi-
al plant belonging to the family of Myrtaceae, is a popular
itchen spice possessing both food and medicinal applications.
t is a rich source of essential oil [12–16% (v/w)] and pheno-
ic compounds [8–12% (w/w) gallic acid equivalent] comprising
ydrolysable tannins, phenolic acids and ﬂavonoids [29]. Clove oil
∗ Corresponding author at: R & D Centre, Akay Flavours & Aromatics Pvt. Ltd.,
mbunadu, Malaidamthuruth PO, Cochin 683561, India.
E-mail address: Krishnakumar.IM@akay-group.com (K. I.M.).
ttp://dx.doi.org/10.1016/j.toxrep.2016.04.001
214-7500/© 2016 Published by Elsevier Ireland Ltd. This is an open access article under license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
and its major component eugenol [70–85% (w/v)], exhibited several
therapeutic effects including antibacterial, antifungal, analgesic,
antispasmodic, anticarminative, antiseptic, and insecticidal effects
in addition to their ﬂavoring applications in food [6,22]. Major phar-
macological activities of clove oil and eugenol include antioxidant,
anti-inﬂammatory, antidiabetic, hypolipidemic, antinociceptive,
hepatoprotective, antiviral and anticancer properties [29,6,22].
Recently, the nonvolatile polyphenols in clove buds were also
shown to be bioactive and started using as dietary supplements
[1,18,20]. Aqueous and alcoholic extracts of clove buds rich in
polyphenols, such as gallic acid, ellagic acid, tannins, ﬂavonoids
and their glycosides were reported to possess aphrodisiac, hypo-
glycemic, gastroprotective, anti-inﬂammatory and antithrombotic
effects [1,18,20]. However, no systematic studies on the oral tox-
icity of clove polyphenols are available to date, except a 28-days
repeated dose toxicity analysis [18].
The US Food and Drug Administration (FDA) has approved clove
buds, clove oil and oleoresins as generally recognised as safe (GRAS)
for use as food additives [38]. While the essential oil is mainly
responsible for the characteristic pungency and aromatic ﬂavor, the
nonvolatile polyphenols provide bitterness and astringency. Clove
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il and eugenol were classiﬁed as minimum risk pesticides by EPA
nd products containing them are exempted from the requirements
f FIFRA [11]. Various acute and chronic toxicity studies of clove oil
ave reported an oral LD50 of 3597.5 mg/kg and has reported no
dverse effects when tested for subchronic toxicity tests, with an
AOEL levels of 900–2000 mg/kg/day [33,40]. Oral LD50 of eugenol
as reported as 2650–3000 mg/kg b.wt. [33,40]. Moreover, eugenol
as shown to be rapidly absorbed, metabolized in the liver and
liminated within 24 h when consumed orally [9].
However, scientiﬁc information on the safety assessment of
love buds or their polyphenol extracts exhibiting signiﬁcant bio-
ogical activity are rare, except a few studies with respect to
esticular function in mice [28] and inhalation toxicity of clove
igarettes [26]. So, there exist a necessity of credible data on the
oxicity aspects of bioactive and standardized extracts of clove buds
o further exploit their functional applications in food, dietary sup-
lements and medicine. Thus, the present study was aimed at the
afety evaluation of a water soluble polyphenol rich extract pow-
er of dried clove buds (hereinafter named as ‘Clovinol’), containing
1.2% gallic acid equivalent of polyphenols. Clovinol was  reported
o possess signiﬁcant in vivo antioxidant, anti-inﬂammatory and
astroprotective activities in alcohol induced ulcerative rat model
18]. It has also been demonstrated to exert signiﬁcant detoxi-
cation potential and cardiac health beneﬁcial effects in human
ubjects, by signiﬁcantly reducing the lipid peroxidation and
nhancing the endogenous redox enzyme levels [20].
. Materials and methods
.1. Preparation and characterization of ‘Clovinol’
Dried clove buds were received from a selected farm in
ndonesia where clove trees are grown without using any pesti-
ides or chemicals. The samples were identiﬁed by an authenticated
otanist and a voucher specimen (AK-CLV-011) was deposited at
he Herbarium of M/s  Akay Flavours & Aromatics Ltd., Cochin, India.
lovinol was prepared by hydro-ethanolic extraction followed by
uriﬁcation and spray drying as reported earlier [18] and found
o contain 41.2% gallic acid equivalent (GAE), when quantiﬁed by
tandard Folin–Ciocalteu test [34]. HPLC analysis was carried out
n a Shimadzu model LC 20 AT, with M20A photo diode array
PDA) detector (Shimadzu Analytical India Pvt. Ltd., Mumbai, India),
tted with a reverse phase C18 column (250 × 4.6 mm,  3 m)  (Phe-
omenex, Hyderabad, India). Characterization of polyphenols was
chieved by 1290 inﬁnity ultra-performance liquid chromatogra-
hy (UPLC) system coupled with Agilent 6530 QTOF instrument
aving a Jet Stream source (Agilent India Pvt. Ltd., Bangalore, India).
mmonium acetate (10 mM)  in water (A) and methanol (B) was
mployed as the mobile phase with a Zorbax Eclipse Plus C18
3.0 × 100 mm;  1.8 m)  column at 30 ◦C and 5 L injection volume.
.2. Animals
Adult Wistar rats (male and female) weighing 170 ± 20 g were
sed for the toxicological studies. The animals were procured from
eterinary College, Mannuthy, Kerala, India and were acclimatized
or a period of 14 days in ventilated cages and housed at the ani-
al  house facility of M/s  Amala Cancer Research Centre, Kerala,
ndia, in an air-conditioned room at 22 ± 2 ◦C and relative humidity
0 ± 5% with 12 h light and dark cycle. All animal experiments were
arried out in strict accordance with the ethical norms approved by
he Institutional Animal Ethics Committee (IAEC) recognized by the
ommittee for the Purpose of Control and Supervision of Exper-
ments on Animals (CPCSEA), Government of India (Registration Reports 3 (2016) 439–449
No:149/99/CPCSEA). Animals were provided with pellet diet and
water ad libitum.
2.3. Toxicity studies
2.3.1. Acute toxicity (14 days) study of ‘Clovinol’
Acute toxicity studies were initially performed to verify whether
Clovinol produced any toxic effects when supplemented at the
maximum recommended concentration. Clovinol was suspended
in water and orally administered as a single dose at the limit dose
of 5 g/kg b.wt. in a sequential manner. Forty rats were divided into
four groups, with each group containing ﬁve animals per sex having
similar weights (170 ± 20 g). Group I was the control (untreated),
and Groups II, III and IV were administered with Clovinol at 1.0, 2.0
and 5.0 g/kg b.wt. respectively. All the animals were observed for
mortality, clinical and behavioral signs for the ﬁrst 10, 30, 60, 120,
240 and 360 min  post dose, and thereafter twice daily for mortality
and once daily for clinical signs during the study period of 14 days.
2.3.2. Subchronic toxicity (90 days) study of ‘Clovinol’
Forty Wistar rats (20 males and 20 females) of average weight
between 150–200 g were selected by stratiﬁed randomization and
then divided into four groups, each consisting of ﬁve males and ﬁve
females of approximately the same body weight. Group I was the
untreated control animals, administered with 1 mL  of water; Group
II, III and IV were orally administered with Clovinol at 0.25, 0.5 and
1.0 g/kg b.wt. respectively for 90 days. Clovinol was suspended in
distilled water and orally administered to the animals using an oral
feeding needle in such a way  that all the animals received same
volume of vehicle. The animals were monitored for any type of clin-
ical symptoms, mortality, and adverse reactions during the study
period. Body weight, food and water consumption were deter-
mined every week for 90 days and expressed for a single cage of
ﬁve animals. After 90 days, the animals were sacriﬁced by cervi-
cal dislocation under ether anesthesia. Necropsy was performed
in the presence of a veterinary doctor and examined visibly for any
type of abnormalities. All the organs were separated and individual
weight was recorded. The weight of brain, liver, stomach, kidney
and spleen were recorded and expressed in relation to the ﬁnal
body weight. The tissue samples were ﬁxed in 10% formalin, and
embedded tissues were cut into slices of 2–4 m and stained with
hematoxylin and eosin for histopathological examinations with
an optical microscope of 100 × magniﬁcations (Olympus-Magnus
trinocular microscope, Tokyo, Japan).
Blood was  collected by direct heart puncture method into
EDTA coated and non-EDTA vials for analyzing the hematologi-
cal parameters and serum biochemistry. Red blood cells (RBCs)
count, total and differential white blood cells (WBCs) count,
platelet levels and hemoglobin (Hb) content were determined
using hematology analyzer (Model-Diatron, Wein, Austria). Serum
was separated by centrifuging at 5000 rpm for 10 min  at −4 ◦C
and was  stored in a clean sample bottle at −20 ◦C for further
analysis. The total bilirubin was determined as detailed by the
Pearlman method [30]; alkaline phosphatase (ALP) was  estimated
by p-nitrophenyl picolinate (PNNP) hydrolysis; alanine amino
transferase (ALT) and aspartate aminotransferase (AST) were esti-
mated using kinetic method kits supplied by M/s  Raichem, India,
using a Microlab 300 auto-analyzer (Merck, Mumbai, India); albu-
min  was determined by its reaction with bromocresol green, and
the total protein concentration was determined by the Biuret
method [25]. Kidney function markers, such as creatinine and
blood urea, were estimated by Jaffe’s kinetic and urease meth-
ods respectively [14]. The total cholesterol was estimated by
the CHOD–PAP (cholesterol oxidase-phenol + aminophenazone)
enzymatic method [10]; triglycerides by the GPO–PAP (glycerol-
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DL cholesterol by precipitation with phosphotungistic acid.
LDL cholesterol was estimated by the Friedewald equation
VLDL = triglyceride/5) and LDL cholesterol by the equation
DL = total cholesterol − (HDL + VLDL). Serum sodium, potassium
nd bicarbonate were estimated using a ﬂame photometer with
n ion selective electrolyte analyzer. Chloride was  estimated by




Evaluation of the ability of Clovinol to induce reverse mutation
t the histidine loci of various Salmonella typhimurium strains TA
8, TA 100 and TA 102 (Ames test) was conducted according to
he standard procedures [3,27]. Mutagenicity of Clovinol was  done
y plate incorporation method in the presence and absence of an
xogenous metabolic activation system at four doses (0.5, 1, 2.5,
 mg/plate), in triplicates for each dose. 2.5 g sodium azide/plate
issolved in distilled sterile water was used as positive control. A
late without drug and mutagens was used as a negative control
nd 200 L DMSO was used as the vehicle control. In the case of
9 mix  activated group, acetamidoﬂuorene (20 g) was  used as
ositive control. 2 mL  top agar layer (0.6% agar and 0.5% NaCl)
ontaining S. typhimurium strains, 0.5 mM histidine–biotin solu-
ion and different concentrations of Clovinol were shaken well and
oured onto 25 mL  of agar. The plates (triplicate) were incubated
or 48 h at 37 ◦C, and revertant colonies were counted using a colony
ounter.
Rat liver microsomal enzyme was used for metabolic activation
f mutagen in vitro [19]. Microsome P450 enzymes was  induced
n rat liver by oral administration of 0.1% phenobarbital dissolved
n water for 4 days. The animals were sacriﬁced on the 5th day
nd the liver were excised aseptically and microsomal S9 fraction
as prepared by centrifuging the homogenate at 9000 g for 15 min.
ctivation mixture was  prepared by mixing S9 mix  (500 L) with
odium phosphate buffer (0.2 M,  pH 7.4), NADP (0.1 M), glucose-6-
hosphate (1 M,  pH 7.4), MgCl2–KCl (10 L) in presence of mutagen,
-acetamidoﬂourene (20 g/plate) or different concentrations of
lovinol and bacterial strains TA 98 and TA 100. The fractions were
ncubated at 37 ◦C for 45 min. Further, it was mixed with 2 mL  of
olten top agar supplemented with histidine and biotin (0.05 mM).
he mixture was shaken well and poured onto the surface of 25 mL
f minimal agar. After 48 h incubation, the mutagenic response was
valuated by counting the revertant colonies per plate and compar-
ng with the control groups. The test substance was considered to
e mutagenic if there was a three- fold increase in the tester strains
hen compared to the negative control.
.4.2. Antimutagenic activity of Clovinol
Antimutagenicity of Clovinol was tested against mutagens such
s sodium azide, NPD and tobacco using S. typhimurium strains TA
00, TA 98 and TA 102 in triplicate [27,23]. Concentrations of Clovi-
ol used for evaluating the antimutagenicity were 0.25, 0.5 and
 mg/plate. Clovinol was added to 2 mL  of top agar at 45 ◦C (0.5%
aCl and 0.6% agar) containing 0.5 mM histidine-biotin, bacterial
ulture of 1–2 × 109 cells/mL (0.1 mL)  and direct acting mutagens
t concentrations mentioned above. It was mixed well and poured
nto minimal agar plates. After incubation at 37 ◦C, the number of
istidine independent revertant colonies was counted using colony
ounter. The plates with mutagen alone acted as positive control
nd plates without test sample and mutagen were considered as
egative controls or spontaneous revertants.
In the case of mutagen needing activation, 2-acetamidoﬂourene
2-AAF) (20 g/plate), Salmonella strains TA 98 or TA 100, differ-
nt concentrations of Clovinol, 0.1 mL  bacteria (1–2 × 109 cells/mL),Reports 3 (2016) 439–449 441
0.5 mL  S9 mix  containing 0.2 M sodium phosphate buffer (pH 7.4),
NADP (0.1 M),  1 M glucose-6-phosphate, 10 L MgCl2–KCl and 2-
AAF were incubated for 45 min  at 37 ◦C. This mixture was  then
added to 2 mL  of melted top agar, gently mixed and overlaid onto
the minimal glucose agar plates. After solidiﬁcation, the plates
were inverted and incubated for 48 h at 37 ◦C. The number of
revertant colonies were counted using colony counter. All the
plates were prepared in triplicate. The percentage inhibition of
mutagenicity was  then calculated using the formula: Percentage
inhibition = [(C − SR) × (T − SR) ÷ (C − SR)] × 100; where ‘C’ is the
number of revertants in the presence of mutagen alone, ‘T’ is the
number of revertants in the presence of Clovinol with mutagens
and ‘SR’ is the spontaneous revertants. The plates with diagnostic
mutagen acted as positive control and plates without test sample
and mutagen were considered as negative controls or spontaneous
revertants.
2.5. Statistical analysis
The values are expressed as mean ± SD. The statistical signiﬁ-
cance was compared between control and experimental groups by
one way analysis of variance (ANOVA) followed by appropriate post
hoc test (Dunnet multiple comparison test) using GraphPad InStat
software (version 3.05). Data of Clovinol treated animals was com-
pared with that of untreated animals, and the differences between
the groups were considered to be signiﬁcant when p < 0.05.
3. Results
3.1. Preparation and characterization of Clovinol
Matured and dried Indonesian clove buds with an average
polyphenol content of 11.5% GAE and 6.6% volatile oil content were
sampled from a 1000 kg lot and used as the plant material for the
preparation of Clovinol. A process of hydro-ethanolic extraction
followed by puriﬁcation, evaporation at controlled temperature
(<50 ◦C) and spray drying was developed for the preparation of
Clovinol as a polyphenol-rich water soluble extract powder. The
free ﬂowing powder of Clovinol showed mild taste and aroma char-
acteristic of clove with a polyphenol content of 41.2% (w/w) as gallic
acid equivalent. Upon nutritional analysis, Clovinol was  found to
contain 46% carbohydrate, 4% protein, 5.3% fat, 1.5% ash and 0.5%
dietary ﬁber. Moisture content was  2.1% with an average density of
0.37 g/mL bulk density, with less than 300 cfu/g total aerobic plate
count and 20 cfu/g total yeast and mold. No traces of Escherichia coli
or Salmonella were detected, indicating its adherence to standard
microbial speciﬁcation for food ingredients.
Tandem mass spectrometric analysis of Clovinol indicated the
presence of various polyphenols including ﬂavonoids, phenolic
acids, hydrolysable tannins, and their glycosides [18,20]. Gallic
acid, ellagic acid, chlorogenic acid, quercetin, luteolin, eugenol, and
eugenol acetate were identiﬁed and conﬁrmed in Clovinol by com-
paring the LC/MS/MS details either with reference compounds or
with literature data. Thus, the major polyphenols in Clovinol were
already shown to be widely present in the plant kingdom and pos-
sess varying health beneﬁcial pharmacological effects. Yet another
concern in Clovinol was the plausible presence of methyleugenol,
a carcinogenic and genotoxic substance reported to be present in
clove oil and extracts [31,36]. Further, GC/M/MS analysis conﬁrmed
the absence of methyleugenol in Clovinol.
3.2. Toxicity studies of Clovinol3.2.1. Acute toxicity study (14 days)
Oral administration of Clovinol at 1, 2 and 5 g/kg body weight
did not produce any mortality or adverse effects during the 14 days





























CFig. 1. Effect of acute administration of Clovinol on (a) body 
eriod of study and also observed no abnormal clinical signs. The
ody weight and food consumption also remain unchanged, when
ompared to the untreated control group of animals (Fig. 1).
.2.2. Subchronic study (90 days)
All animals in the Clovinol treated groups, at doses of 0.25,
.5 and 1 g/kg b.wt. survived until the scheduled necropsy on day
1 was performed. No treatment related abnormalities in clin-
cal and/or behavioral signs were observed as compared to the
ntreated control group of animals.
.2.2.1. Effect on body weight. The weight gain among both
he male and female animals in the untreated and treated
roups was normal (p > 0.05) (Fig. 2). During 90 days of study
eriod, the body weight (g) of untreated control male ani-
als increased from 190.6 ± 28.7 to 295.3 ± 24.8 with an average
rowth rate of 1.16 ± 0.03 g/day and that of female animals
ncreased from 162.5 ± 12.8 to 241.2 ± 15.9 with a growth factor of
.87 ± 0.02 g/day respectively. Clovinol treated (0.25, 0.5 and 1.0 g
er kg b.wt.) animals also showed no signiﬁcant difference in the
eight gain and growth rate among the male and female animals
hen compared to the untreated control group of animals. The
ody weight (g) of male rats administered with high dose (1 g/kg
.wt.) of Clovinol was found to be increased from 174.5 ± 12.7 to
74.8 ± 23.3 with a growth rate of 1.11 ± 0.08 per day and that
f female rats increased from 167.6 ± 11.4 to 249.7 ± 10.9 with a
rowth rate of 0.91 ± 0.01 per day. A similar trend was  observed
ith the lower doses of Clovinol as well (0.25 and 0.5 g/kg b.wt.)Fig. 2).
.2.2.2. Effect on food and water consumption. Administration of
lovinol at 0.25 g/kg (Group II), 0.5 g/kg (Group III) and 1 g/kgt and (b) food consumption pattern of male and female rats.
(Group IV) doses did not produce any signiﬁcant difference
(p > 0.05) in the food consumption of male and female rats when
compared to untreated group of animals (Fig. 3). The average food
intake of male rats was nearly 2.62 g/animal/day and that of female
was 2.21 g/animal/day. Water consumption of the Clovinol treated
animals also remained unchanged when compared with untreated
control animals.
3.2.2.3. Urinalysis. There were no signiﬁcant changes in either the
pH (6.5–7.5) or in the volume of urine collected from the Clovinol
treated animals when compared with untreated. Microscopy of the
urinary sediment did not reveal any calcium or phosphate crystals.
Urinary glucose, albumin and keto acids were also absent in both
treated and untreated animals.
3.2.2.4. Ophthalmic observations. Ophthalmoscopic observations
did not reveal any treatment related changes to conclude corneal
ulcer or retinal vascularity. There was  neither compression of reti-
nal vessels nor extra branching of vessels, ruling out the plausible
lesions like glaucoma or intraocular inﬂammatory changes due to
Clovinol administration.
3.2.2.5. Necropsy and organ weights. Necropsy of the treated ani-
mals showed normal appearance of various organs and tissues. The
weight of organs (heart, liver, spleen, kidney and brain) relative to
the body weight showed no signiﬁcant changes (p > 0.05) among
the various treated animals when compared with the untreated
control group of male and female animals (Table 1).3.2.2.6. Hematological parameters. Clovinol did not produce any
signiﬁcant (p > 0.05) changes in the hematological parameters.
Hemoglobin, WBC, RBC, platelet counts and differential counts
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Fig. 2. Effect of sub-chronic administration of Clovinol on body weight of (a) male and (b) female rats.
Table 1
Effect of 90 days administration of Clovinol on organ weight.
Organs Dose groupa
Males Females
Control 0.25 g/kg 0.5 g/kg 1 g/kg Control 0.25 g/kg 0.5 g/kg 1 g/kg
Liver (g) 3.46 ± 0.12 3.29 ± 0.27 3.57 ± 0.12 3.64 ± 0.24 3.52 ± 0.68 3.49 ± 0.35 3.60 ± 0.48 3.11 ± 0.28
Kidney  (g) 0.80 ± 0.16 0.86 ± 0.10 0.87 ± 0.13 0.84 ± 0.08 0.68 ± 0.15 0.76 ± 0.09 0.78 ± 0.04 0.68 ± 0.08
Heart  (g) 0.75 ± 0.14 0.79 ± 0.17 0.89 ± 0.21 0.77 ± 0.16 0.84 ± 0.06 0.83 ± 0.16 0.82 ± 0.12 0.74 ± 0.11
Spleen  (g) 0.47 ± 0.06 0.45 ± 0.04 0.46 ± 0.18 0.44 ± 0.08 0.35 ± 0.06 0.37 ± 0.04 0.45 ± 0.05 0.40 ± 0.09








calues are mean ± standard deviation, expressed as the organ weight/100 g of body
a 5 animals/sex/group, unless otherwise speciﬁed.
lymphocyte, eosinophil and neutrophils) of Clovinol treated ani-
als remained in the normal range, when compared to the
ntreated control group of animals (Table 2)..2.2.7. Serum biochemical parameters. Clovinol administration did
ot produce any signiﬁcant changes on biochemical parameters
elated to hepatic and renal function as compared to the untreated
ontrol group of animals. Renal function parameters such as bloodht.
urea, serum creatinine and electrolytes in both male and female rats
were comparable to the untreated control animals after 90 days of
supplementation (Table 3). Hepatic function markers such as ALT,
AST, ALP, total bilirubin, total protein and A/G ratio were not altered
in Clovinol treated animals of both sexes (Table 4). Lipid proﬁle also
remained unchanged with no signiﬁcant (p > 0.05) variation in total
cholesterol, HDL, LDL and VLDL cholesterol levels among both male
and female rats, and were comparable to that of untreated control
444 L. Vijayasteltar et al. / Toxicology Reports 3 (2016) 439–449
Fig. 3. Effect of subchronic administration of Clovinol on food consumption of (a) male and (b) female rats.
Table 2
Effect of 90 days administration of Clovinol on hematological parameters.
Measured parameters Dose groupa
Males Females
Control 0.25 g/kg 0.5 g/kg 1 g/kg Control 0.25 g/kg 0.5 g/kg 1 g/kg
Hb (g/dL) 14.84 ± 0.67 16.05 ± 0.95 15.3 ± 0.36 15.52 ± 1.38 14.22 ± 0.32 13.66 ± 1.45 14.90 ± 1.24 14.62 ± 0.76
WBC  (× 103/mm3) 6.62 ± 3.14 8.38 ± 2.18 8.62 ± 2.31 7.66 ± 1.80 7.30 ± 2.40 7.40 ± 1.98 8.10 ± 2.83 8.24 ± 1.08
RBC  (× 106/mm3) 5.76 ± 0.75 5.74 ± 0.88 5.24 ± 0.82 6.13 ± 1.25 5.94 ± 0.79 5.41 ± 0.78 5.37 ± 0.77 5.99 ± 1.12
Platelet  (× 105/mm3) 7.51 ± 0.35 8.61 ± 0.44 7.48 ± 0.17 7.85 ± 0.61 7.19 ± 0.18 6.86 ± 0.96 6.90 ± 0.68 6.85 ± 0.19
Lymphocytes (× 103/mm3) 4.72 ± 2.26 5.44 ± 2.85 5.98 ± 1.27 5.42 ± 1.22 4.99 ± 1.61 5.56 ± 1.57 5.76 ± 2.17 5.59 ± 1.99
Eosinophils (× 102/mm3) 5.75 ± 2.62 5.57 ± 2.61 4.86 ± 2.13 5.25 ± 1.84 6.01 ± 2.81 5.43 ± 2.26 5.93 ± 1.90 5.84 ± 2.67
Neutrophils (× 102/mm3) 13.29 ± 6.73 16.09 ± 6.08 15.76 ± 3.47 14.52 ± 5.65 16.59 ± 7.09 14.92 ± 3.69 17.45 ± 5.61 15.77 ± 4.20
Abbreviations: Hb, hemoglobin; WBC, white blood cells; RBC, red blood cells.
The values are expressed as mean ± standard deviation.
a 5 animals/sex/group, unless otherwise speciﬁed.
Table 3
Effect of 90 days administration of Clovinol on renal function parameters.
Measured parameters Dose groupa
Males Females
Control 0.25 g/kg 0.5 g/kg 1 g/kg Control 0.25 g/kg 0.5 g/kg 1 g/kg
Urea (mg/dL) 15.40 ± 2.70 12.25 ± 1.89 14.75 ± 2.22 12.20 ± 2.39 14.20 ± 1.48 13.20 ± 2.28 12.00 ± 0.82 14.60 ± 2.19
Creatinine (mg/dL) 0.33 ± 0.08 0.28 ± 0.05 0.31 ± 0.05 0.26 ± 0.09 0.28 ± 0.08 0.30 ± 0.05 0.27 ± 0.05 0.32 ± 0.08
Na  (mEq/L) 143.00 ± 1.58 138.50 ± 1.29 145.00 ± 3.56 141.00 ± 1.58 141.20 ± 1.30 137.20 ± 2.17 137.75 ± 1.71 142.00 ± 1.87
K  (mEq/L) 6.66 ± 0.19 5.83 ± 0.77 6.65 ± 0.84 6.32 ± 0.31 6.02 ± 1.02 6.12 ± 0.96 5.73 ± 0.39 5.64 ± 0.36
Cl  (mEq/L) 102.59 ± 2.96 98.00 ± 3.58 94.68 ± 6.42 97.66 ± 2.70 96.00 ± 3.90 104.86 ± 4.76 98.03 ± 3.00 98.04 ± 4.20
HCO3 (mEq/L) 24.40 ± 2.07 25.00 ± 1.83 25.00 ± 1.41 24.60 ± 0.89 25.00 ± 1.58 25.40 ± 2.07 24.00 ± 0.82 25.20 ± 1.92
Abbreviations: Na, sodium; K, potassium; Cl, chloride; HCO3, bicarbonate.
The values are expressed as mean ± standard deviation.
a 5 animals/sex/group, unless otherwise speciﬁed.
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Table  4
Effect of 90 days administration of Clovinol on hepatic function markers.
Measured parameters Dose groupa
Males Females
Control 0.25 g/kg 0.5 g/kg 1 g/kg Control 0.25 g/kg 0.5 g/kg 1 g/kg
ALT (U/L) 65.00 ± 4.74 58.25 ± 7.5 61.84 ± 5.26 59.20 ± 9.56 68.72 ± 12.54 61.20 ± 7.39 59.50 ± 11.90 55.80 ± 9.25
AST  (U/L) 174.80 ± 26.28 182.55 ± 20.47 169.72 ± 28.69 147.40 ± 32.30 171.40 ± 22.58 165.20 ± 29.35 180.75 ± 19.91 179.24 ± n25.45
ALP  (U/L) 274.60 ± 42.69 280.25 ± 38.8 264.50 ± 34.38 278.20 ± 40.03 316.00 ± 59.80 283 ± 55.04 265.00 ± 49.08 270.60 ± 51.82
Bilirubin (mg/dL) 0.48 ± 0.09 0.45 ± 0.12 0.40 ± 0.08 0.42 ± 0.09 0.38 ± 0.11 0.42 ± 0.07 0.43 ± 0.05 0.39 ± 0.09
Albumin (g/dL) 3.14 ± 0.17 2.55 ± 0.19 2.95 ± 0.26 2.76 ± 0.27 2.90 ± 0.10 2.86 ± 0.13 3.03 ± 0.28 2.82 ± 0.15
Globulin (g/dL) 2.36 ± 0.21 1.90 ± 0.14 1.78 ± 0.17 2.25 ± 0.28 2.50 ± 0.26 2.24 ± 0.21 2.45 ± 0.10 2.30 ± 0.33
A/G  ratio 1.15 ± 0.14 1.09 ± 0.25 1.27 ± 0.40 1.06 ± 0.16 1.02 ± 0.15 1.12 ± 0.39 1.09 ± 0.24 1.04 ± 0.16
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase.
The  values are expressed as mean ± standard deviation.
a 5 animals/sex/group, unless otherwise speciﬁed.
Table 5
Effect of 90 days administration of Clovinol on lipid proﬁle.
Measured parameters Dose groupa
Males Females
Control 0.25 g/kg 0.5 g/kg 1 g/kg Control 0.25 g/kg 0.5 g/kg 1 g/kg
Cholesterol (mg/dL) 64.60 ± 13.97 60.25 ± 9.50 61.50 ± 12.65 57.20 ± 15.25 65.40 ± 15.60 61.25 ± 16.92 62.80 ± 12.43 56.00 ± 9.73
Triglycerides (mg/dL) 54.20 ± 24.60 46.60 ± 13.45 57.25 ± 29.90 51.60 ± 17.24 41.00 ± 5.58 36.50 ± 7.29 39.65 ± 4.35 36.82 ± 9.95
HDL  (mg/dL) 24.40 ± 1.14 24.00 ± 1.71 23.00 ± 1.82 25.15 ± 1.09 21.60 ± 1.14 23.91 ± 2.23 22.05 ± 0.80 22.25 ± 1.17
LDL  (mg/dL) 19.50 ± 3.39 17.00 ± 3.56 20.00 ± 4.16 18.79 ± 2.40 21.20 ± 6.62 16.60 ± 4.20 18.75 ± 3.50 20.40 ± 4.50
VLDL  (mg/dL) 12.61 ± 2.45 11.75 ± 3.26 10.50 ± 3.58 11.40 ± 2.55 14.80 ± 5.17 11.40 ± 3.88 12.35 ± 6.14 12.80 ± 4.07


































Mutagenic study of Clovinol on Salmonella typhimurium strains using reverse muta-
tion  assay.
Doses of Clovinol (mg/plate) TA 98 TA 100 TA102
Without S9-mix Number of revertants
Negative controlb 68.5 ± 4.9 82 ± 2.1 70 ± 1.4
Positive controlc 378 ± 19 817 ± 61 973 ± 63
5  53.5 ± 4.9 63 ± 3.5 75 ± 4.2
2.5  66 ± 2.8 71 ± 12 70 ± 3.5
1  75 ± 15.5 79 ± 0.7 70 ± 6.4
0.5  72 ± 9.4 80 ± 11.6 73 ± 9.1
With S9-mix Number of revertants
Negative controlb 78 ± 1.4 93 ± 17.7 128 ± 7.1
Positive controlc 587 ± 43 687 ± 56 467 ± 39
5  73 ± 3.5 66 ± 2.8 132 ± 2.8
2.5  70 ± 4.9 71 ± 2.1 125 ± 4.9
1  78 ± 2.8 89 ± 12.7 127 ± 2.8
0.5  76 ± 7.3 91 ± 16.4 125 ± 12.3
The values are mean ± standard deviation of 3 different determinations. Acetamid-bbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, ve
he  values are expressed as mean ± standard deviation.
a 5 animals/sex/group, unless otherwise speciﬁed.
roup (Table 5). However, a decreasing trend on total cholesterol
nd triglycerides has been observed among animals treated with
.5 and 1 g/kg body weight of Clovinol.
.2.2.8. Histopathological analysis. The histopathological examina-
ion of various organs of animals treated with 1.0 g/kg b.wt. of
lovinol showed normal cellular architecture when compared with
hose of the untreated groups of animals (Fig. 4). The tissue sections
f spleen from Clovinol treated animals showed normal lym-
hoid follicles with areas prominent in germinal centers. Medullary
egion showed sinusoidal congestion, lymphostasis and histiocytic
roliferation with cellular architecture and morphology similar to
hat of untreated control animals. The liver section of Clovinol
reated animals showed normal portal triads and central venous
ystem; normal hepatocytes were arranged in cords with Kupffer
ells and showed normal sinusoidal spaces, which were identical
ith those from the untreated animals. The histopathology of kid-
ey tissues of Clovinol treated animals showed normal glomeruli
ith Bowman’s capsule adrenal tubules. The interstitial tissues
ppeared with no apparent abnormalities when compared with the
issues of untreated group of animals. The section of brain tissues
f Clovinol administered rats showed hyperplasia of the astrocytes
ith pleomorphism. There were occasional mitotic cells, normal
lial cells and the interstitial tissues. The cerebellum of the Clovinol
reated animals appeared normal with an overall cellular architec-
ure and morphology similar to the brain from untreated animals.
.3. Genotoxicity studies
.3.1. Mutagenicity of Clovinol
Clovinol did not show any substantial increase in revertants inny of the strains of S. typhimurium when used either in the pres-
nce or in the absence of metabolic activation (S9 mix) (Table 6).
hile positive controls containing the known mutagens resulted
n a signiﬁcant (p < 0.05) increase in the revertant colonies in eachoﬂuorene (2-AAF) was used as mutagen in studies involving S9 activities.
b Spontaneous reversion (without mutagen and drug).
c Mutagen treated (NPD for TA 98; NaN3 for TA 100 and TA 102).
strain, vehicle control did not produced any change. The sponta-
neous reversion rates in the negative and positive control were
within the normal range which suggested that Clovinol did not
induce any gene mutation or frame shifts in the genome of the
strains under the speciﬁc conditions of the experiment.
3.3.2. Antimutagenicity of Clovinol
Antimutagenic activity of Clovinol was evaluated at three dif-
ferent concentrations (0.25, 0.5 and 1 mg/plate) employing the
strains of S. typhimurium (TA 98, TA 100 and TA 102) in the pres-
ence of known mutagens (NaN3, NPD, 2-AAF and tobacco). Strains
produced several fold revertant colonies upon treatment with
mutagens. However, Clovinol treatment exhibited a concentra-
tion dependent antimutagenic activity when investigated with and










(Fig. 4. Histological sections of various organs of animals
ithout activation. When used at 1 mg/plate concentration, Clovi-
ol signiﬁcantly inhibited NaN3-induced mutagenicity by 57.2% on
A100 and 39.6% on TA102 strains (Fig. 5a). NPD induced muta-
enicity was found to be inhibited by 67.2% and 29.1% respectively
hen used at the same concentration of 1 mg/plate concentration
Fig. 5b). Clovinol also exhibited 33.7% of antimutagenicity against
obacco extract in Salmonella strain TA 102 at a concentration of
 mg/plate (Fig. 5c). Moreover, Clovinol also exhibited signiﬁcant
p < 0.001) antimutagenic activity (28.9% and 25.92% at the con-ing 90 days of administration of Clovinol at 1 g/kg b.wt.
centration of 1 mg/plate in Salmonella TA 98 and TA 100 strains
respectively) upon metabolic activation with 2-AAF (Fig. 5d).
4. DiscussionEven though clove buds, clove oleoresin and its essential oil
have given the status of GRAS for use as a natural food ﬂavor,
systematic investigations on the safety of clove polyphenols have
not been reported to date [29,38,11]. Eugenol, the major com-
































rig. 5. Antimutagenic activity of Clovinol against NaN3, NPD, tobacco and 2-AAF usin
xtract (d) 2-acetamidoﬂourene (2-AAF). The values are mean ± standard deviation o
ontrol; SR = spontaneous revertants.
onent in clove oil, has been approved with an allowable daily
ntake level of 2.5 mg/kg body weight for humans [24]. However,
he major components of Clovinol used in the present study were
olyphenols (41.2%) which is different from the compositions of
love oil or oleoresin commonly approved as a food additive.
n addition, Clovinol was also shown to be bioactive exhibiting
ntioxidant, anti-inﬂammatory and antiulcerogenic effects [18,20].
n open label human intervention study also demonstrated the
igniﬁcant effect of Clovinol to upregulate the endogenous antiox-
dant enzymes (glutathione, superoxide dismutase, glutathione
eroxidase, and catalase) and to reduce lipid peroxidation when
onsumed either as 250 mg  capsules per day or as a dietary ingre-
ient [20]. Thus, the present investigation reported the acute and
ubchronic toxicity studies and genotoxicity of Clovinol prepared
y a hydro-ethanolic extraction followed by puriﬁcation, concen-
ration and spray drying process as a free ﬂowing water soluble
owder suitable for the dietary intervention either as a func-
ional/medical food ingredient or as dietary supplement.
The absence of abnormalities or adverse effects observed upon
he acute oral toxicity study of Clovinol at 5 g/kg body weight indi-
ated its primary safety. The fact that all the animals survived
ntil the scheduled necropsy on 91st day and the absence of any
igniﬁcant changes in various parameters including changes in
ody weight, food and water consumption, heamatological param-
ters, biochemical parameters, organ toxicity and histopathology of
rgan tissues further demonstrated the safety of Clovinol upon the
epeated dose oral administrations at 0.25, 0.5 and 1 g/kg b.wt. for
0 days. The lack of signiﬁcant changes in both physical appearance
nd behavioral patterns further revealed the absence of treatment-
elated adverse effects of Clovinol. Changes in body weight andes assay (a) sodium azide (NaN3) (b) 4-nitro-O-phenylenediamine (NPD) (c) tobacco
e different determinations. Where *p < 0.05, **p < 0.01 when compared with positive
food/water consumption have generally been regarded as a pre-
liminary indication of adverse effect of a drug [37]. The absence of
signiﬁcant changes in hematology parameters (hemoglobin, RBC
count, platelet count, total and differential leukocytes count), as
compared to the untreated control group of animals, also indicated
the safety of Clovinol supplementation. Hematopoietic system was
generally considered as one of the most sensitive set of parame-
ters to assess the safety of a drug [5]. Yet another set of sensitive
parameters include the liver and renal function markers [12]. Ele-
vation of ALT levels in serum was usually regarded as the ﬁrst
response of liver cell damage [2]. The observation that the chronic
administration of Clovinol at 1 g/kg body weight for 90 days did not
induce any signiﬁcant changes in liver function markers, except a
toxicologically irrelevant increase in albumin/globulin ratio, indi-
cated its hepatic safety. The absence of changes in the lipid proﬁle
can also be correlated to the liver health, since liver is the site
for cholesterol degradation and glucose synthesis [4]. The present
study demonstrated no changes in LDL, HDL and VLDL level with
a non-signiﬁcant reduction in triglyceride levels, which indicated
the normal lipid and carbohydrate metabolism of Clovinol treated
animals. Similarly, the absence of signiﬁcant changes in serum urea,
creatinine and electrolytes (sodium, potassium, chlorine and bicar-
bonate) pointed towards its safety on renal functions. An increase
in the serum creatinine levels generally correlated to the damage
of functional nephrons [16]. Moreover, the absence of either the
weight changes or morphological abnormalities of vital organs, as
revealed by the macroscopic and histopathological investigations,
also pointed towards the safety of Clovinol even upon repeated dose
consumption for 90 days. Thus, the present study demonstrated
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or Clovinol having a total polyphenol content of 41.2% gallic acid
quivalent. A previous study (28-days repeated dose acute toxi-
ity study) also reported that the supplementation of Clovinol at
 g/kg body weight did not induce any mortality, adverse effects,
linical or behavioral symptoms, or changes in hematological and
iochemical parameters [18].
Ames test, one of the most consistent test for detecting geno-
oxic and carcinogenic substances, was employed for evaluating
he mutagenicity and antimutagenic activities of Clovinol [27,23].
he fact that Clovinol (0.1–10 mg/plate) did not produce any rever-
ants during the Ames test indicated the absence of dose related
utagenicity of Clovinol either with or without metabolic acti-
ation. Thus the mutagenic study showed that Clovinol does not
ct as a genotoxic material. Genotoxic substances are potentially
nown to be mutagenic or carcinogenic [27]. Moreover, Clovinol
lso exhibited signiﬁcant inhibition of the mutagenicity produced
y the direct acting mutagens, like sodium azide, NPD and tobacco.
odium azide is a potent mutagen against plants, mammals and
acteria with high speciﬁcity towards Salmonella and E. coli species
35]. NPD is a mutagen often found to contaminate cosmetics,
hich induce frame shift mutation in S. typhimurium [7]. Tobacco
as also demonstrated to contain many carcinogenic compounds
15]. In the present study, it was observed that Clovinol inhibited
he activation of 2-AAF, a potent arylamine carcinogen whose acti-
ation was known to be by cytochrome p450 enzymes in liver.
hus, the antimutagenic property of Clovinol may  be due to the
nactivation of mutagens by inhibition of free radicals or activa-
ion of cellular antioxidant enzymes as well as by inhibition of
ytochrome p450 enzymes and/or by increased detoxiﬁcation of
utagens [39,17]. Earlier studies on Clovinol has already demon-
trated its radical scavenging activities and detoxiﬁcation potential
y enhancing the cellular antioxidant defense enzymes includ-
ng glutathione, glutathione peroxidase, superoxide dismutase, and
atalase in both animals and humans [18,20]. Signiﬁcant antimuta-
enic activity of Clovinol may  also be linked to its anticarcinogenic
otential which need to be further evaluated.
. Conclusions
The present study reported the safety evaluation of a polyphe-
ol rich extract of clove buds (Clovinol) as shown by the acute
14 days) and subchronic oral gavage at 1 g/kg b. wt. for 90 days
nd mutagenicity studies. Clovinol did not produce any signiﬁcant
hanges in body weight, food and water consumption, hemato-
ogical and/or biochemical parameters. Histological examinations
f selected organs also supported the safety of Clovinol. Clovi-
ol did not produce any mutagenicity to Salmonella strains with
nd without activation of S9 mixture upto a concentration of
 mg/plate. Moreover, Clovinol has shown signiﬁcant antimuta-
enic potential against some of the known mutagens as well as
gainst 2-AAF, which needs metabolic activation for mutagenicity.
hus, the results of the present study indicated that Clovinol is safe
n rats with an NOAEL of 1 g/kg body weight per day and can be
urther considered for human consumption.
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